Combination Therapy as a Promising Way to Fight Oral Cancer.
João P N SilvaBárbara PintoLuís Silva MonteiroPatrícia M A SilvaHassan BousbaaPublished in: Pharmaceutics (2023)
Oral cancer is a highly aggressive tumor with invasive properties that can lead to metastasis and high mortality rates. Conventional treatment strategies, such as surgery, chemotherapy, and radiation therapy, alone or in combination, are associated with significant side effects. Currently, combination therapy has become the standard practice for the treatment of locally advanced oral cancer, emerging as an effective approach in improving outcomes. In this review, we present an in-depth analysis of the current advancements in combination therapies for oral cancer. The review explores the current therapeutic options and highlights the limitations of monotherapy approaches. It then focuses on combinatorial approaches that target microtubules, as well as various signaling pathway components implicated in oral cancer progression, namely, DNA repair players, the epidermal growth factor receptor, cyclin-dependent kinases, epigenetic readers, and immune checkpoint proteins. The review discusses the rationale behind combining different agents and examines the preclinical and clinical evidence supporting the effectiveness of these combinations, emphasizing their ability to enhance treatment response and overcome drug resistance. Challenges and limitations associated with combination therapy are discussed, including potential toxicity and the need for personalized treatment approaches. A future perspective is also provided to highlight the existing challenges and possible resolutions toward the clinical translation of current oral cancer therapies.
Keyphrases
- combination therapy
- locally advanced
- epidermal growth factor receptor
- dna repair
- radiation therapy
- signaling pathway
- squamous cell carcinoma
- primary care
- rectal cancer
- randomized controlled trial
- neoadjuvant chemotherapy
- dna damage
- minimally invasive
- tyrosine kinase
- clinical trial
- stem cells
- cardiovascular disease
- oxidative stress
- risk assessment
- climate change
- cardiovascular events
- lymph node
- skeletal muscle
- cell cycle
- pi k akt
- metabolic syndrome
- percutaneous coronary intervention
- insulin resistance
- atrial fibrillation
- coronary artery disease
- dna damage response
- induced apoptosis
- radiation induced
- open label
- human health